What is the difference between Miralax (Polyethylene Glycol 3350) and PEG 3350 for treating constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

MiraLAX and PEG 3350 Are the Same Medication

MiraLAX is simply the brand name for polyethylene glycol (PEG) 3350, making them chemically identical products with the same efficacy, safety profile, and mechanism of action. 1, 2

Understanding PEG 3350

Mechanism of Action

  • PEG 3350 is a long-chain polymer of ethylene oxide that acts as an osmotic laxative
  • It works by attracting water into the colon, which softens stool and increases bowel movements
  • Unlike stimulant laxatives, it does not cause dependency or significant electrolyte disturbances

Formulation and Administration

  • Standard dosage: 17g of powder dissolved in 8 ounces (240mL) of liquid once daily
  • Can be mixed with water, juice, coffee, or tea at any temperature
  • Available as:
    • Brand name (MiraLAX) in powder form
    • Generic PEG 3350 in identical formulation
    • Some versions include electrolytes (PEG-E), though the standard U.S. formulation typically does not

Efficacy for Constipation

PEG 3350/MiraLAX has demonstrated significant efficacy in treating constipation:

  • Increases complete spontaneous bowel movements (CSBMs) by approximately 2.9 per week compared to placebo 1
  • Increases spontaneous bowel movements (SBMs) by approximately 2.3 per week 1
  • Achieves success rates of 52% for chronic constipation versus 11% for placebo over 6 months 3
  • Demonstrates superior efficacy compared to other medications like tegaserod 4 and comparable efficacy to prucalopride 5

Safety Profile

The safety profile of PEG 3350/MiraLAX is well-established:

  • Well-tolerated with minimal side effects
  • Common side effects include bloating, flatulence, abdominal discomfort, and loose stools
  • No significant differences in laboratory findings compared to placebo in long-term studies 3
  • Safe for use in elderly patients 3
  • No risk of dependency or tolerance development

Duration of Use

  • FDA-approved for short-term treatment of occasional constipation
  • Clinical evidence supports safe and effective use for up to 6 months for chronic idiopathic constipation 1, 3
  • The American Gastroenterological Association suggests it can be used earlier in the treatment algorithm for chronic idiopathic constipation, either after a trial of fiber supplementation or in combination with fiber 1

Cost Considerations

  • Generally more cost-effective than prescription constipation medications
  • Available over-the-counter, eliminating the need for prescription costs
  • Monthly cost ranges from $10-$45 depending on brand versus generic 2

Clinical Applications

PEG 3350/MiraLAX is recommended for:

  • Chronic idiopathic constipation (CIC) 1
  • Irritable bowel syndrome with constipation (IBS-C), though evidence is limited 1
  • Medication-induced constipation 2, 6

Important Considerations

  • Higher doses (51-85g) may provide more rapid relief within 24 hours for acute constipation 7
  • Standard 17g dose typically produces effects within 2-4 days of regular use
  • Avoid use in patients with known or suspected bowel obstruction
  • No significant drug interactions have been reported

Remember that while MiraLAX is a brand name and PEG 3350 is the generic name, they contain the same active ingredient and work through the same mechanism, making them therapeutically equivalent.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Constipation Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

OTC polyethylene glycol 3350 and pharmacists' role in managing constipation.

Journal of the American Pharmacists Association : JAPhA, 2012

Research

Overnight efficacy of polyethylene glycol laxative.

The American journal of gastroenterology, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.